The covariates were adjusted in the PSM model for a priori-identified potential confounders, such as age, sex, race/ethnicity, nicotine dependence, BMI, type 2 diabetes, hypertension, hyperlipidaemia, hypercholesterolaemia, chronic respiratory disease, chronic renal diseases, BP, chronic kidney disease, peripheral vascular diseases, diabetes-related microvascular complications, glomerular diseases, cirrhosis of the liver, osteoporosis, sleep apnoea, abnormal laboratory findings (HbA 1c , serum cholesterol, LDL-cholesterol, HDL-cholesterol and triacylglycerol [TG]) and intake of cardiovascular medications (Table 1)
Understanding Insurance Coverage for Weight Loss Medications When it comes to getting weight loss drugs covered by insurance, the first thing to understand is that coverage variessometimes significantlydepending on your specific health plan and the medication in question
The medication remains in Phase 3 clinical trials
GLP 1 agonistleri etki mekanizmas da doal hormonun yapt bu ilevleri taklit eder